A Phase 1 interventional study of Carfilzomib in Solid Tumors, Hematologic Malignancies and Hepatic Impairment, sponsored by Amgen. Completed at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.
Sponsored by Amgen · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.
Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 295th largest by enrollment of the 658 interventional ones that give a count, is one of 31 that started in 2013, is one of 195 in phase 1, and was the 261st registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.
Browse Hematologic Neoplasms studies →181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Orum Therapeutics USA, Inc. · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
821 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 276 · Phase 2 280 · Phase 3 43 · Phase 4 9
First in 1989; this study’s year is marked. 31 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is close to the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 40 across the 658 interventional studies, 150 across the 157 observational. Of the 497 that completed or were terminated, 208 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 821 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 4 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
90 of the studies in Hematologic Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT04188418Phase 3M.D. Anderson Cancer CenterFentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients | 2027-08-31 |
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT02203903Catherine BollardMulti-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies | 2026-11-30 |
Add all 90 to your calendar (.ics) → With an account.
Among the 821 studies in Hematologic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and efficacy of carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with varying degrees of liver function to see if they respond differently to the study drug.
Key Inclusion Criteria:
Clinical diagnosis of chronic hepatic impairment that is stable with no acute worsening of liver failure within one month prior to enrollment. Hepatic impairment will be assessed as per National Cancer Institute Organ Dysfunction Working Group Criteria (NCI-ODWG) schema and will fall into one of the following three categories:
Exception to Inclusion Criterion #5 for Subjects with Normal Hepatic Function:
All subjects enrolled with normal hepatic function (N=10) must meet all inclusion criteria as outlined with the exception of Inclusion Criterion
#5, which should be substituted with the following criterion to be enrolled into the study:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal hepatic function (bilirubin and aspartate aminotransferase (AST) ≤ the upper limit of normal (ULN)) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
Drug: Carfilzomib
Participants with mild hepatic impairment (bilirubin \> 1-1.5 x ULN or AST \> ULN, but bilirubin ≤ ULN) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
Drug: Carfilzomib
Participants with moderate hepatic impairment (bilirubin \> 1.5-3 x ULN, any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
Drug: Carfilzomib
(Bilirubin \> 3 × ULN; any AST) Participants with severe hepatic impairment (bilirubin \> 3 x ULN; any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
Drug: Carfilzomib
Carfilzomib was administered by IV injection over 30 minutes
Also known as: Kyprolis® (carfilzomib) for Injection
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 27 mg/m²
The area under the curve from time zero (defined as the start of carfilzomib infusion) to the last concentration measured (AUC0-last) following intravenous administration of carfilzomib 27 mg/m² on day 16 of cycle 1 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.
Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²
The area under the curve from time zero extrapolated to infinity (AUC0-inf) following intravenous administration of carfilzomib 27 mg/m² on day 16 of cycle 1 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.
Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Maximum Plasma Concentration (Cmax) of Carfilzomib 27 mg/m²
Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 27 mg/m²
Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Clearance of Carfilzomib 27 mg/m²
Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life of Carfilzomib 27 mg/m²
Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Mean Residence Time (MRT) of Carfilzomib 27 mg/m²
Time frame: Cycle 1 day 16, pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Volume of Distribution at Steady State (Vss) of Carfilzomib 27 mg/m²
Time frame: Cycle 1 day 16 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 56 mg/m²
The area under the curve from time zero to the last concentration measured (AUC0-last) following intravenous administration of carfilzomib 56 mg/m² on day 1 of cycle 2 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.
Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 56 mg/m²
The area under the curve from time zero extrapolated to infinity (AUC0-inf) following intravenous administration of carfilzomib 56 mg/m² on day 1 of cycle 2 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.
Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Maximum Plasma Concentration (Cmax) of Carfilzomib 56 mg/m²
Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 56 mg/m²
Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life of Carfilzomib 56 mg/m²
Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Clearance of Carfilzomib 56 mg/m²
Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Mean Residence Time (MRT) of Carfilzomib 56 mg/m²
Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Volume of Distribution at Steady State (Vss) of Carfilzomib 56 mg/m²
Time frame: Cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-389/M14
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-389/M14
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Maximum Plasma Concentration (Cmax) for Metabolite PR-389/M14
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-389/M14
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life for Metabolite PR-389/M14
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Mean Residence Time (MRT) for Metabolite PR-389/M14
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-413/M15
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-413/M15
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Maximum Plasma Concentration (Cmax) for Metabolite PR-413/M15
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-413/M15
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life for Metabolite PR-413/M15
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Mean Residence Time (MRT) for Metabolite PR-413/M15
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-519/M16
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-519/M16
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Maximum Plasma Concentration (Cmax) for Metabolite PR-519/M16
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-519/M16
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life for Metabolite PR-519/M16
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Mean Residence Time (MRT) for Metabolite PR-519/M16
Time frame: Cycle 1 day 16 and cycle 2 day 1 pre-dose, 15 minutes after the start of infusion, immediately (within 2 minutes) before the end of infusion, and at 5, 15, and 30 minutes and 1, 2, and 4 hours after the end of the infusion.
Number of Participants With Adverse Events (AEs)
Treatment-related adverse events (TRAEs) are adverse events considered related to carfilzomib by the investigator, including those with unknown relationship. Adverse events were graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, on a scale from 1 (mild) to 5 (death).
Time frame: From the first dose of carfilzomib until 30 days after last dose; the overall median duration of treatment was 4.2 weeks
| Milestone | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Started | 11 | 17 | 14 | 4 |
| Completed | 11 | 17 | 14 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
The area under the curve from time zero (defined as the start of carfilzomib infusion) to the last concentration measured (AUC0-last) following intravenous administration of carfilzomib 27 mg/m² on day 16 of cycle 1 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 27 mg/m² | 378 ± 40.8 | 546 ± 39.2 | 477 ± 33.1 | — |
The area under the curve from time zero extrapolated to infinity (AUC0-inf) following intravenous administration of carfilzomib 27 mg/m² on day 16 of cycle 1 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m² | 348 ± 35.4 | 529 ± 40.3 | 500 ± 38.4 | — |
| ng/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Carfilzomib 27 mg/m² | 932 ± 58.4 | 1290 ± 47.5 | 1020 ± 43.7 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 27 mg/m² | 0.292 (0.250 to 0.500) | 0.458 (0.250 to 0.667) | 0.483 (0.233 to 0.750) | — |
| L/hour | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Clearance of Carfilzomib 27 mg/m² | 157 ± 32.5 | 86.4 ± 50.9 | 103 ± 43.9 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Terminal Half-life of Carfilzomib 27 mg/m² | 0.469 ± 22.8 | 0.541 ± 75.9 | 0.511 ± 219.4 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Mean Residence Time (MRT) of Carfilzomib 27 mg/m² | 0.108 ± 60.6 | 0.167 ± 45.7 | 0.235 ± 70.4 | — |
| liters | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Volume of Distribution at Steady State (Vss) of Carfilzomib 27 mg/m² | 16.9 ± 37.0 | 14.4 ± 58.1 | 24.2 ± 66.0 | — |
The area under the curve from time zero to the last concentration measured (AUC0-last) following intravenous administration of carfilzomib 56 mg/m² on day 1 of cycle 2 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 56 mg/m² | 765 ± 100.5 | 1107 ± 73.7 | 927 ± 45.8 | — |
The area under the curve from time zero extrapolated to infinity (AUC0-inf) following intravenous administration of carfilzomib 56 mg/m² on day 1 of cycle 2 was calculated using a non-compartmental approach, from the individual plasma concentration profiles of carfilzomib.
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 56 mg/m² | 609 ± 99.6 | 1108 ± 73.7 | 929 ± 46.2 | — |
| ng/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Carfilzomib 56 mg/m² | 1697 ± 93.7 | 2733 ± 67.0 | 2119 ± 47.9 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 56 mg/m² | 0.300 (0.250 to 0.583) | 0.408 (0.250 to 0.683) | 0.400 (0.250 to 0.583) | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Terminal Half-life of Carfilzomib 56 mg/m² | 0.508 ± 54.7 | 0.621 ± 47.7 | 0.740 ± 137.7 | — |
| L/hour | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Clearance of Carfilzomib 56 mg/m² | 181 ± 95.9 | 92.0 ± 77.2 | 121 ± 43.5 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Mean Residence Time (MRT) of Carfilzomib 56 mg/m² | 0.0834 ± 195.6 | 0.161 ± 43.6 | 0.164 ± 30.7 | — |
| liters | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Volume of Distribution at Steady State (Vss) of Carfilzomib 56 mg/m² | 15.0 ± 52.2 | 14.8 ± 51.9 | 19.8 ± 36.7 | — |
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0 | 463 ± 42.5 | 417 ± 30.5 | 385 ± 26.8 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 837 ± 26.8 | 752 ± 29.7 | 786 ± 20.3 | — |
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 4, 11, 8, 0 | 400 ± 19.3 | 432 ± 29.9 | 437 ± 32.7 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 4, 6, 5, 0 | 834 ± 6.3 | 770 ± 27.2 | 843 ± 22.3 | — |
| ng/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0 | 189 ± 32.5 | 198 ± 22.7 | 201 ± 26.5 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 381 ± 15.0 | 345 ± 25.9 | 513 ± 24.3 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0 | 0.867 (0.583 to 1.52) | 0.792 (0.633 to 1.50) | 0.750 (0.583 to 1.00) | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 0.842 (0.750 to 1.48) | 0.992 (0.750 to 1.60) | 0.750 (0.650 to 0.783) | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 4, 11, 8, 0 | 1.42 ± 10.3 | 1.20 ± 13.7 | 1.26 ± 18.0 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 4, 6, 5, 0 | 1.32 ± 15.3 | 1.30 ± 16.1 | 1.07 ± 13.6 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 4, 11, 8, 0 | 2.42 ± 11.4 | 2.13 ± 12.2 | 2.14 ± 16.0 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 4, 6, 5, 0 | 2.25 ± 10.8 | 2.27 ± 15.8 | 1.78 ± 11.2 | — |
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0 | 50.1 ± 39.5 | 56.7 ± 33.9 | 85.5 ± 36.6 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 106 ± 33.7 | 119 ± 38.9 | 173 ± 17.8 | — |
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 13, 8, 0 | 56.6 ± 43.7 | 60.8 ± 32.6 | 92.9 ± 41.7 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 116 ± 36.9 | 132 ± 41.0 | 186 ± 18.2 | — |
| ng/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0 | 27.8 ± 30.5 | 33.9 ± 30.7 | 46.3 ± 26.6 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 59.4 ± 27.5 | 66.0 ± 37.2 | 103 ± 19.5 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0 | 0.750 (0.583 to 0.767) | 0.767 (0.583 to 1.00) | 0.650 (0.583 to 1.10) | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 0.717 (0.600 to 1.00) | 0.800 (0.467 to 1.08) | 0.750 (0.617 to 0.750) | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 13, 8, 0 | 1.34 ± 18.9 | 1.25 ± 13.6 | 1.23 ± 17.6 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 1.18 ± 21.8 | 1.24 ± 10.2 | 1.07 ± 16.0 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 13, 8, 0 | 2.13 ± 15.8 | 2.02 ± 8.8 | 2.04 ± 14.6 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 1.96 ± 18.9 | 2.09 ± 8.0 | 1.83 ± 8.9 | — |
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0 | 125 ± 27.6 | 136 ± 45.2 | 228 ± 37.3 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 278 ± 23.4 | 311 ± 42.9 | 463 ± 24.5 | — |
| ng*hr/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 8, 0 | 127 ± 27.8 | 138 ± 44.9 | 235 ± 39.4 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 7, 8, 5, 0 | 281 ± 25.6 | 314 ± 42.7 | 465 ± 24.4 | — |
| ng/mL | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0 | 145 ± 30.7 | 160 ± 42.0 | 257 ± 43.6 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 314 ± 33.6 | 349 ± 39.5 | 546 ± 23.4 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 9, 0 | 0.500 (0.250 to 0.667) | 0.600 (0.250 to 0.750) | 0.700 (0.583 to 0.850) | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 0.483 (0.250 to 0.617) | 0.592 (0.250 to 0.850) | 0.583 (0.467 to 0.650) | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 8, 0 | 0.786 ± 14.0 | 0.728 ± 22.6 | 0.673 ± 13.6 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 7, 8, 5, 0 | 0.748 ± 22.2 | 0.680 ± 10.7 | 0.601 ± 8.2 | — |
| hours | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Cycle 1 Day 16 (27 mg/m²); N = 10, 14, 8, 0 | 1.01 ± 11.3 | 0.961 ± 29.1 | 0.994 ± 13.3 | — |
| Cycle 2 Day 1 (56 mg/m²); N = 8, 8, 5, 0 | 0.994 ± 9.0 | 1.00 ± 14.2 | 0.909 ± 7.8 | — |
Treatment-related adverse events (TRAEs) are adverse events considered related to carfilzomib by the investigator, including those with unknown relationship. Adverse events were graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, on a scale from 1 (mild) to 5 (death).
| participants | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Any adverse event | 10 | 17 | 14 | 4 |
| Adverse event Grade ≥ 3 | 7 | 12 | 13 | 3 |
| Serious adverse events | 3 | 10 | 8 | 4 |
| Leading to discontinuation of carfilzomib | 1 | 2 | 4 | 0 |
| Fatal adverse events | 1 | 4 | 1 | 3 |
| Treatment-related adverse events (TRAE) | 8 | 13 | 12 | 1 |
| Treatment-related adverse events Grade ≥ 3 | 2 | 5 | 8 | 0 |
| Treatment-related serious adverse events | 0 | 3 | 4 | 0 |
| TRAE leading to discontinuation of carfilzomib | 1 | 0 | 3 | 0 |
| Treatment-related fatal adverse events | 0 | 2 | 0 | 0 |
Collected over From the first dose of carfilzomib until 30 days after last dose; the overall median duration of treatment was 4.2 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal Hepatic Function | — | 3/11 (27.3%) | 10/11 (90.9%) |
| Mild Hepatic Impairment | — | 10/17 (58.8%) | 17/17 (100%) |
| Moderate Hepatic Impairment | — | 8/14 (57.1%) | 14/14 (100%) |
| Severe Hepatic Impairment | — | 4/4 (100%) | 3/4 (75%) |
| Event | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| Hepatic encephalopathyNervous system disorders | 0/11 | 0/17 | 0/14 | 2/4 |
| Acute kidney injuryRenal and urinary disorders | 0/11 | 0/17 | 1/14 | 2/4 |
| Multi-organ failureGeneral disorders | 0/11 | 0/17 | 0/14 | 1/4 |
| Acute hepatic failureHepatobiliary disorders | 0/11 | 0/17 | 0/14 | 1/4 |
| Bacterial sepsisInfections and infestations | 0/11 | 0/17 | 0/14 | 1/4 |
| Septic shockInfections and infestations | 0/11 | 0/17 | 0/14 | 1/4 |
| AscitesGastrointestinal disorders | 0/11 | 0/17 | 3/14 | 0/4 |
| Blood bilirubin increasedInvestigations | 0/11 | 0/17 | 2/14 | 0/4 |
| Lower respiratory tract infectionInfections and infestations | 1/11 | 1/17 | 0/14 | 0/4 |
| PneumoniaInfections and infestations | 1/11 | 1/17 | 0/14 | 0/4 |
| Event | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|---|
| FatigueGeneral disorders | 8/11 | 7/17 | 8/14 | 0/4 |
| Blood bilirubin increasedInvestigations | 0/11 | 1/17 | 9/14 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 6/11 | 10/17 | 3/14 | 2/4 |
| DiarrhoeaGastrointestinal disorders | 4/11 | 4/17 | 4/14 | 1/4 |
| Oedema peripheralGeneral disorders | 4/11 | 2/17 | 5/14 | 0/4 |
| NauseaGastrointestinal disorders | 3/11 | 5/17 | 5/14 | 0/4 |
| ConstipationGastrointestinal disorders | 1/11 | 5/17 | 4/14 | 0/4 |
| Alanine aminotransferase increasedInvestigations | 1/11 | 5/17 | 4/14 | 0/4 |
| Decreased appetiteMetabolism and nutrition disorders | 3/11 | 5/17 | 2/14 | 0/4 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/11 | 1/17 | 4/14 | 0/4 |
| Age, Continuous(years) | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Mean | 68.5 ± 8.2 | 59.5 ± 9.1 | 61.0 ± 7.9 | 56.3 ± 10.9 | 61.8 ± 9.3 |
| Age, Customized(participants) | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| < 65 years | 3 | 12 | 8 | 3 | 26 |
| ≥ 65 years | 8 | 5 | 6 | 1 | 20 |
| Sex: Female, Male(Participants) | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Female | 2 | 8 | 5 | 3 | 18 |
| Male | 9 | 9 | 9 | 1 | 28 |
| Race/Ethnicity, Customized(participants) | Normal Hepatic Function | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Black | 0 | 1 | 1 | 0 | 2 |
| White | 11 | 13 | 13 | 4 | 41 |
| Not reported | 0 | 3 | 0 | 0 | 3 |
The record gives a start of Oct 2013, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib